Cannabis drug preparations have been employed medicinally in folk medicine since antiquity, and were extensively used in western medicine between the middle of the 19th century and World War II, particularly as a substitute for opiates (Mikuriya 1969). A bottle of commercial medicinal extract is shown in Fig. 41. Medical use declined with the introduction of synthetic analgesics and sedatives, and there is very limited authorized medical use today, but considerable unauthorized use, including so-called “compassion clubs” dispensing marijuana to gravely ill people, which has led to a momentous societal and scientific debate regarding the wisdom of employing cannabis drugs medically, given the illicit status. There is anecdotal evidence that cannabis drugs are useful for: alleviating nausea, vomiting, and anorexia following radiation therapy and chemotherapy; as an appetite stimulant for AIDS patients; for relieving the tremors of multiple sclerosis and epilepsy; and for pain relief, glaucoma, asthma, and other ailments [see Mechoulam and Hanus (1997) for an authoritative medical review, and Pate (1995) for a guide to the medical literature]. To date, governmental authorities in the US, on the advice of medical experts, have consistently rejected the authorization of medical use of marijuana except in a handful of cases. However, in the UK medicinal marijuana is presently being produced sufficient to supply thousands of patients, and Canada recently authorized the cultivation of medicinal marijuana for compassionate dispensation, as well as for a renewed effort at medical evaluation.
Last year, the National Academies of Sciences, Engineering and Medicine released a nearly 500-page report on the health effects of cannabis and cannabinoids. A committee of 16 experts from a variety of scientific and medical fields analyzed the available evidence — more than 10,000 scientific abstracts in all. Because so few studies examine the effects of CBD on its own, the panel did not issue any findings about CBD specifically, but it did reach some conclusions about cannabis and cannabinoids more generally. The researchers determined that there is “conclusive or substantial evidence” supporting the use of cannabis or cannabinoids for chronic pain in adults, multiple sclerosis-related spasticity (a kind of stiffness and muscle spasms), and chemotherapy-induced nausea and vomiting. The committee also found “moderate” evidence that cannabis or cannabinoids can reduce sleep disturbances in people with obstructive sleep apnea, fibromyalgia, chronic pain and multiple sclerosis, as well as “limited” evidence that these substances can improve symptoms of Tourette’s syndrome, increase appetite and stem weight loss in people with HIV/AIDs, and improve symptoms of PTSD and anxiety.
Out of the 17 states that have passed CBD-only laws, five— Missouri, Florida, Mississippi, Louisiana, and Texas—would also establish licensed cultivation centers to grow high-CBD strains of cannabis, which could be turned into oils and other CBD products. This would cut down on the demand for CBD oil from unregulated manufacturers abroad. Even then, though, impediments remain. In Missouri, for example, two neurologists recently refused to prescribe CBD oil for an eight- year-old boy suffering from seizures, citing concerns over federal law and the safety of non-FDA approved products.
The U.S. hemp-derived CBD market alone is projected to reach $450 million by 2020, and China's cannabis market could grow to 100 billion yuan by 2022 (approximately $14.5 billion). Hemp is already interwoven into the futures of the automotive, construction, energy, environmental mediation and technology industries. Once fully utilized and legal, this plant could impact the global economic positionings of North America, China and Africa.
A short-term Advisory Board has been appointed to serve through the development of the rules and regulations. The rules and regulations themselves will identify the guidelines for formation of the Advisory Board, so upon adoption of the rules and regulations an Advisory Board will be created which will continue on a regular basis beyond that point.
I suffer fr migraines. Currently having Botox injections every three months for the last three years. This has helped went fr 24 to 30 migraines a month to 6 to 8 , now I'm back up to 14 to 20 a month. My doctor thought CBD oil might help. I have also started having anxiety attacks for a year now. I'm really confused with the dosages. Any thoughts would b helpful
For patients suffering from seizures, the legalization of cannabis would be a decisive turning point. Epilepsy makes you desperate. Seizures are painful, sometimes debilitating. And then there are the aftershocks: broken teeth, bruises and cuts, lost time, humiliation. People with epilepsy are often depressed, and have more than double the suicide rate of the population at large. Epilepsy is also associated with a syndrome known as Sudden Unexpected Death in Epilepsy, wherein a previously healthy person with epilepsy simply dies without warning or explanation. Grinding on without relief isn’t an option, but getting help is enormously expensive. Research conducted by Charles Begley, a professor of public health at the University of Texas, found that epilepsy treatment costs between $8,500 and $11,000 per year. Real Scientific Hemp Oil is no less expensive than its pharmaceutical counterparts, with no assistance from insurance. A single three-gram vial costs $149, while a six-pack of 10-gram tubes can cost $1,999 (or $1,599 on sale). HempMedsPx suggests a “serving size” of 0.5 ml twice daily. Only when these drugs are recognized as such will insurance pick up the tab.